Semaglutide PEN 5mg/pen

Semaglutide PEN 5mg/pen
Hilma Biocare

Specifications Semaglutide (pre-filed pen):

Active Half-life : approximately 1 week (165–184 hours)
Group: Peptide hormone
Subgroup: Injection / lyophilized powder
Dosage: 5 mg
Application (Men): 2,5 to 15 mg
Product pack:  3 ml (Injection Pen)
Content (active): Semaglutide
Retains water: not recognized
Aromatization: No

Product Description

Semaglutide is a glucagon-like peptide-1 receptor agonist. It is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. Semaglutide is not for use in people with type 1 diabetes. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in patients. The higher-dose formulation of Semaglutide is indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity (initial body mass index (BMI) ≥ 30 kg/m2) or who are overweight (initial BMI ≥ 27 kg/m2) and have at least one weight-related comorbidity.

Action:

Semaglutide reduces high blood sugar by increasing the amount of insulin released, decreasing the amount of glucagon released, and delaying gastric emptying. Semaglutide also controls appetite and helps reduce the amount of food a person wants to eat. In addition, Semaglutide reduces preference for high-fat meals.

Dosage:

The beginning dose is 0.25 mg once a week for the first 4 weeks. This will help give your body a chance to get used to the medicine. At Week 5, your health care professional will increase the dose to 0.5 mg once a week.combination with any AAS.